Patamostat mesylate | CAS# 114568-32-0 (mesylate) | trypsin inhibitor

MedKoo Cat#: 414793 | Name: Patamostat mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Patamostat mesylate, a guanidinobenzoate, is a trypsin inhibitor which is being developed by Eisai for the treatment of acute pancreatitis.

Chemical Structure

Patamostat mesylate

CAS#114568-32-0 (mesylate)

Theoretical Analysis

MedKoo Cat#: 414793

Name: Patamostat mesylate

CAS#: 114568-32-0 (mesylate)

Chemical Formula: C21H24N4O7S2

Exact Mass:

Molecular Weight: 508.56

Elemental Analysis: C, 49.60; H, 4.76; N, 11.02; O, 22.02; S, 12.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

114568-32-0 (mesylate); 114568-26-2 (free base)

Synonym

Patamostat mesylate; E3123; E-3123; E 3123

IUPAC/Chemical Name

Benzoic acid, 4-((aminoiminomethyl)amino)-, 4-((2-(2,5-dioxo-1-pyrrolidinyl)ethyl)thio)phenyl ester, monomethanesulfonate

InChi Key

HTSFLDCSCNSKJW-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H20N4O4S.CH4O3S/c21-20(22)23-14-3-1-13(2-4-14)19(27)28-15-5-7-16(8-6-15)29-12-11-24-17(25)9-10-18(24)26;1-5(2,3)4/h1-8H,9-12H2,(H4,21,22,23);1H3,(H,2,3,4)

SMILES Code

O=C(OC1=CC=C(SCCN2C(CCC2=O)=O)C=C1)C3=CC=C(NC(N)=N)C=C3.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 508.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Iwatsuki K, Horiuchi A, Yonekura H, Ren LM, Chiba S. E-3123, a new synthetic protease inhibitor, protects against deoxycholic acid-induced acute pancreatitis in dogs. Arch Int Pharmacodyn Ther. 1990 Nov-Dec;308:168-77. PMID: 1711836. 2: Satake K, Ha SS, Hiura A, Nishiwaki H. The therapeutic effect of a new synthetic protease inhibitor (E-3123) on hemodynamic changes during experimental acute pancreatitis in dogs. Gastroenterol Jpn. 1993 Feb;28(1):64-71. doi: 10.1007/BF02775005. PMID: 8440425. 3: Miyamoto K, Hishinuma I, Nagakawa J, Nagaoka N, Yamanaka T, Wakabayashi T. [Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis]. Nihon Yakurigaku Zasshi. 1988 May;91(5):285-93. Japanese. doi: 10.1254/fpj.91.285. PMID: 3410375. 4: Kazama M, Kobayashi K, Tahara C, Miyajima Y, Endo Y, Tanaka H, Nakatani T, Tajimi K. [Improving effect of the synthetic protease inhibitor E-3123 on experimental DIC in dogs]. Nihon Yakurigaku Zasshi. 1992 Jul;100(1):47-58. Japanese. doi: 10.1254/fpj.100.47. PMID: 1644370. 5: Hirano T, Manabe T, Ohshio G, Nio Y. Improved survival in mice with diet- induced pancreatitis treated with new potent protease inhibitor, E-3123 and a broad spectrum antibiotic, cefmetazole. Nihon Geka Hokan. 1992 May 1;61(3):213-23. PMID: 1444701. 6: Hirano T, Manabe T. A new synthetic protease inhibitor, E-3123, prevents lysosomal and mitochondrial fragility in rat caerulein-induced pancreatitis. J Int Med Res. 1992 Jun;20(3):211-7. doi: 10.1177/030006059202000302. PMID: 1383065. 7: Hirano T, Manabe T. Effect of short-term pancreatico-biliary duct obstruction with intraductal hypertension on subcellular organelle fragility and pancreatic adenylate energy metabolism in rats: protective effect of a new protease inhibitor, E-3123. Acta Chir Belg. 1994 Mar-Apr;94(2):80-5. PMID: 7517090. 8: Hirano T, Manabe T, Yotsumoto F, Ohshio G, Nio Y. Effect of short-termed pancreatico-biliary duct obstruction on lysosomal enzyme in rats: protective effect of a potent new protease inhibitor, E-3123. Nihon Geka Hokan. 1992 May 1;61(3):234-48. PMID: 1280076. 9: Nishiwaki H, Ko I, Hiura A, Ha SS, Satake K, Sowa M. Renal microcirculation in experimental acute pancreatitis of dogs. Ren Fail. 1993;15(1):27-31. doi: 10.3109/08860229309065568. PMID: 8441833. 10: Hirano T, Manabe T, Imanishi K, Yotsumoto F, Kyogoku T, Tobe T. A new synthetic protease inhibitor, E-3123, reduces organelle fragility of acinar cells in rat caerulein pancreatitis. Nihon Geka Hokan. 1991 Nov 1;60(6):406-14. PMID: 1820013.